Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol
Objectives. Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods. In our double-blind, placebo-controlled human clinical trial, we...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2020/7262474 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567978854449152 |
|---|---|
| author | Roland Gal Dora Praksch Peter Kenyeres Miklos Rabai Kalman Toth Robert Halmosi Tamas Habon |
| author_facet | Roland Gal Dora Praksch Peter Kenyeres Miklos Rabai Kalman Toth Robert Halmosi Tamas Habon |
| author_sort | Roland Gal |
| collection | DOAJ |
| description | Objectives. Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods. In our double-blind, placebo-controlled human clinical trial, we enrolled 60 outpatients with heart failure. Patients were randomized into two groups: receiving either 100 mg resveratrol capsule daily or placebo for 3 months. Hematocrit was determined by microhematocrit centrifuge. Plasma and whole blood viscosity was evaluated by capillary viscometer. Erythrocyte aggregation was measured by both LORCA and Myrenne aggregometers. LORCA ektacytometer was used for measuring erythrocyte deformability. Exercise capacity was assessed by a 6-minute walk test. Results. Resveratrol treatment did not have any significant effect on hematocrit and viscosity. The erythrocyte deformability also remained unchanged. However, significant improvement of red blood cell aggregation was observed in the resveratrol group compared to baseline after 3 months. Furthermore, positive correlation was found between the exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability) as well. Conclusion. These findings indicate that resveratrol can significantly reduce red blood cell aggregation, which may positively influence microcirculation, which may contribute to the improvement of tissue perfusion and oxygen supply in heart failure. |
| format | Article |
| id | doaj-art-f3fed748077b44c5babe979bf0e3e952 |
| institution | Kabale University |
| issn | 1755-5914 1755-5922 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-f3fed748077b44c5babe979bf0e3e9522025-02-03T01:00:07ZengWileyCardiovascular Therapeutics1755-59141755-59222020-01-01202010.1155/2020/72624747262474Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by ResveratrolRoland Gal0Dora Praksch1Peter Kenyeres2Miklos Rabai3Kalman Toth4Robert Halmosi5Tamas Habon6Division of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryDivision of Cardiology, 1st Department of Medicine, Medical School, University of Pécs, HungaryObjectives. Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods. In our double-blind, placebo-controlled human clinical trial, we enrolled 60 outpatients with heart failure. Patients were randomized into two groups: receiving either 100 mg resveratrol capsule daily or placebo for 3 months. Hematocrit was determined by microhematocrit centrifuge. Plasma and whole blood viscosity was evaluated by capillary viscometer. Erythrocyte aggregation was measured by both LORCA and Myrenne aggregometers. LORCA ektacytometer was used for measuring erythrocyte deformability. Exercise capacity was assessed by a 6-minute walk test. Results. Resveratrol treatment did not have any significant effect on hematocrit and viscosity. The erythrocyte deformability also remained unchanged. However, significant improvement of red blood cell aggregation was observed in the resveratrol group compared to baseline after 3 months. Furthermore, positive correlation was found between the exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability) as well. Conclusion. These findings indicate that resveratrol can significantly reduce red blood cell aggregation, which may positively influence microcirculation, which may contribute to the improvement of tissue perfusion and oxygen supply in heart failure.http://dx.doi.org/10.1155/2020/7262474 |
| spellingShingle | Roland Gal Dora Praksch Peter Kenyeres Miklos Rabai Kalman Toth Robert Halmosi Tamas Habon Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol Cardiovascular Therapeutics |
| title | Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol |
| title_full | Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol |
| title_fullStr | Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol |
| title_full_unstemmed | Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol |
| title_short | Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol |
| title_sort | hemorheological alterations in patients with heart failure with reduced ejection fraction treated by resveratrol |
| url | http://dx.doi.org/10.1155/2020/7262474 |
| work_keys_str_mv | AT rolandgal hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol AT dorapraksch hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol AT peterkenyeres hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol AT miklosrabai hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol AT kalmantoth hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol AT roberthalmosi hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol AT tamashabon hemorheologicalalterationsinpatientswithheartfailurewithreducedejectionfractiontreatedbyresveratrol |